Diadema Partners’s Pyxis Oncology PYXS Stock Holding History

Diadema Partners’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.17M	Buy	+388,200	New	+$742K	0.15%	102

Other funds holding PYXS

GGI

GordonMD Global Investments Beverely Hills, California $207M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Diadema Partners's PYXS Position: Q4 2025 in Review

Diadema Partners sold out of Pyxis Oncology (PYXS) in Q4 2025, closing a stake of 150,000 shares — an estimated $333K sold.

Diadema Partners first reported a position in PYXS in Q3 2025 and held it in 1 quarter. The position peaked at $333K in Q3 2025. 79 funds tracked by Wall St. Rank hold PYXS as of Q4 2025.

Diadema Partners reported no remaining Pyxis Oncology position as of Q4 2025 after selling out during the quarter.
Diadema Partners sold 150,000 Pyxis Oncology shares in Q4 2025, an estimated $333K.
Diadema Partners first reported a position in Pyxis Oncology in Q3 2025 and held it in 1 quarter.
Diadema Partners's Pyxis Oncology position peaked at $333K in Q3 2025.
79 funds tracked by Wall St. Rank held Pyxis Oncology as of Q4 2025.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.